- Trial phase
- Approved
- Time to market
- Already on the market since 2014. A potential DSWPD label expansion is at least 12-18 months away (sNDA submission and FDA review cycle ahead; no PDUFA date set).
- Why 3/10
- HETLIOZ is already approved and commercialized with no pending dated regulatory decision; the DSWPD sNDA submission is planned but has no scheduled PDUFA date, and the jet lag hearing outcome is not a hard dated binary. Per the rubric, an approved marketed drug with no imminent new regulatory decision scores 3-5, and the heavily generic-eroded revenue stream further caps the HETLIOZ-specific impact.
Watch for Vanda's DSWPD sNDA submission timeline and any FDA feedback from planned discussions; also monitor the formal evidentiary hearing on the jet lag rejection. Neither has a fixed date, so HETLIOZ-specific binary catalysts are not imminent. Vanda's near-term value is more tied to the imsidolimab PDUFA (December 12 2026) and Fanapt commercial trends than to HETLIOZ.
Price Chart
Executive Summary
HETLIOZ (tasimelteon) is Vanda Pharmaceuticals' FDA-approved melatonin receptor agonist for Non-24-Hour Sleep-Wake Disorder in blind adults and for nighttime sleep disturbances in Smith-Magenis Syndrome. The drug faces severe generic competition that has slashed its net product sales 66% year-over-year to $5.6 million in Q2 2026 (bouncing to $21.7M in Q3 on shipment timing). Two FDA rejections for a jet lag label expansion and a June 2026 formal hearing contesting that refusal add regulatory uncertainty. Positive Phase 3 results in Delayed Sleep-Wake Phase Disorder (DSWPD) announced Sept 29 2026 offer a potential lifeline, but an sNDA submission has no scheduled date. HETLIOZ is increasingly a minor revenue contributor versus Vanda's lead asset Fanapt.
How It Works
A melatonin receptor agonist, meaning it mimics the body's natural sleep hormone melatonin to help reset the internal body clock (circadian rhythm) to a 24-hour schedule. It selectively activates MT1 and MT2 receptors in the brain that regulate sleep-wake timing.
Trial Status
HETLIOZ is FDA-approved for two indications (Non-24-Hour Sleep-Wake Disorder in adults and nighttime sleep disturbances in Smith-Magenis Syndrome for ages 16+ capsules / ages 3-15 oral suspension). A Phase 3 study in Delayed Sleep-Wake Phase Disorder (DSWPD) met its primary endpoint in September 2026, and Vanda plans to discuss the data with the FDA and submit a supplemental NDA. The FDA rejected an sNDA for jet lag disorder in January 2026 (second rejection), and a formal evidentiary hearing on that refusal was granted in June 2026.
The Two-Sided Case
Upcoming Catalysts
- DSWPD sNDA submission to FDA (no date announced yet)
- Outcome of formal FDA evidentiary hearing on jet lag disorder application (granted June 2026, status unclear)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vanda Pharmaceuticals Inc. 8-K VNDA ·Originating report